Drug:
Reaction: PRURITUS
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555316 |
US |
||
Pruritus, Urticaria, Drug ineffective, |
||||
OMALIZUMAB, |
||||
| 2 | 26555445 |
AR |
67 | 1 |
Urticaria, Pruritus, Rash, Acne pustular, Dry skin, Epistaxis, Skin fissures, Miliaria, Perioral dermatitis, Sensitive skin, Skin burning sensation, Erythema, Lip dry, Skin disorder, Off label use, |
||||
PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, |
||||
| 3 | 26555447 |
US |
60 | 1 |
Cerebrovascular accident, Pruritus, |
||||
RISANKIZUMAB-RZAA, |
||||
| 4 | 26555605 |
US |
46 | 2 |
Erythema, Dyspnoea, Pruritus, Injection site pruritus, Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 5 | 26555648 |
CA |
86 | 2 |
Blood creatinine increased, Pruritus, Rash, |
||||
PANTOPRAZOLE, APIXABAN, BISOPROLOL FUMARATE, CALCIUM CARBONATE, ANTACID, CANDESARTAN, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ERGOCALCIFEROL, POLYETHYLENE GLYCOL, LEVOTHYROXINE SODIUM, |
||||
| 6 | 26555886 |
US |
||
Pruritus, Hypersensitivity, Drug ineffective, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 7 | 26556074 |
AR |
66 | 2 |
Anal incontinence, Rectal haemorrhage, Hepatitis, Skin burning sensation, Swollen tongue, Mouth swelling, Eating disorder, Pain, Rash, Pruritus, Exfoliative rash, Decreased immune responsiveness, Colostomy bag user, Acne pustular, Ill-defined disorder, Rash macular, Erythema, Blister, Malaise, Discomfort, Skin haemorrhage, Dysarthria, Drug ineffective, Dry skin, Off label use, Drug hypersensitivity, Flatulence, Blood test abnormal, Magnetic resonance imaging abnormal, Therapy interrupted, Musculoskeletal pain, |
||||
PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, PANITUMUMAB, |
||||
| 8 | 26556132 |
CA |
74 | |
Spinal disorder, Drug intolerance, Asthenia, Dizziness, Pruritus, Nausea, Drug ineffective, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, RITUXIMAB, RITUXIMAB, ADALIMUMAB-ADAZ, METHOTREXATE, METHOTREXATE SODIUM, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE, |
||||
| 9 | 26556190 |
US |
||
Eye swelling, Pruritus, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 10 | 26556487 |
US |
59 | 2 |
Condition aggravated, Pruritus, Arthralgia, Myalgia, Ulcer, |
||||
DASATINIB, |
||||
| 11 | 26556666 |
US |
32 | |
Hypoaesthesia, Paraesthesia, Pruritus, Contusion, Influenza like illness, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 12 | 26556688 |
CA |
63 | 2 |
Alopecia, Application site reaction, Chronic spontaneous urticaria, Depression, Dyspnoea, Dyspnoea exertional, Haemorrhage, Headache, Hepatic enzyme increased, Urticaria, Tachycardia, Insomnia, Intervertebral disc protrusion, Malaise, Middle insomnia, Muscular weakness, Pain, Paraesthesia, Primary biliary cholangitis, Pruritus, Scratch, Skin burning sensation, Skin lesion, Skin plaque, Spinal meningeal cyst, Stress, Erythema, Product dose omission issue, Drug ineffective, Incorrect dose administered, Inappropriate schedule of product administration, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, NICOTINE, NICOTINE POLACRILEX, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, |
||||
| 13 | 26556731 |
CA |
2 | |
Feeling abnormal, Gait inability, Movement disorder, Drug hypersensitivity, Injection site pain, Erythema, Myalgia, Insomnia, Cough, Gait disturbance, Nasopharyngitis, Pruritus, |
||||
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, |
||||
| 14 | 26556858 |
US |
61 | 2 |
Pruritus, |
||||
TRALOKINUMAB-LDRM, |
||||
| 15 | 26556944 |
US |
38 | 2 |
Pruritus, Sleep disorder, Skin fissures, Blister, Dry skin, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 16 | 26556949 |
US |
49 | 2 |
Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 17 | 26556951 |
US |
44 | 2 |
Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 18 | 26557139 |
AR |
65 | 2 |
Metastases to liver, Post procedural complication, Colon operation, Nasal discomfort, Feeling cold, Muscle spasms, Blister, Diarrhoea, Nausea, Dry skin, Nail disorder, Feeling hot, Pruritus, Gastrointestinal disorder, Vision blurred, Sneezing, Onychomadesis, Skin haemorrhage, Rhinitis, Skin laceration, Sensory loss, Retching, Limb injury, Impaired healing, Temperature intolerance, Loss of personal independence in daily activities, Pain in extremity, Nasal dryness, Cough, Epistaxis, Skin fissures, Rash, Localised infection, Acne, Erythema, Drug ineffective, Muscle spasms, |
||||
PANITUMUMAB, OXALIPLATIN, OXALIPLATIN, |
||||
| 19 | 26557157 |
US |
2 | |
Paraesthesia, Pruritus, Rash pruritic, |
||||
ALIROCUMAB, |
||||
| 20 | 26557159 |
US |
22 | 2 |
Urticaria, Pruritus, Swelling, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 21 | 26557163 |
US |
41 | 2 |
Pruritus, Skin haemorrhage, |
||||
DUPILUMAB, |
||||
| 22 | 26557165 |
US |
66 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 23 | 26557166 |
US |
29 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 24 | 26557168 |
US |
2 | 1 |
Dry skin, Skin haemorrhage, Sleep disorder due to a general medical condition, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 25 | 26557170 |
US |
46 | 1 |
Pruritus, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 26 | 26557181 |
US |
2 | |
Pruritus, Urticaria, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 27 | 26557184 |
US |
4 | 1 |
Dry skin, Pruritus, Injection site reaction, |
||||
DUPILUMAB, |
||||
| 28 | 26557243 |
US |
58 | 2 |
Eczema, Pruritus, Sleep disorder due to a general medical condition, Dry skin, Skin exfoliation, Injection site bruising, |
||||
DUPILUMAB, |
||||
| 29 | 26557288 |
CA |
38 | 2 |
Ear pruritus, Inappropriate schedule of product administration, Off label use, Pruritus, Throat irritation, |
||||
RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIMENHYDRINATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, |
||||
| 30 | 26557295 |
CN |
62 | 2 |
Urticaria, Pruritus, Rash, |
||||
FRUQUINTINIB, |
||||
| 31 | 26557317 |
US |
88 | 1 |
Pruritus, Skin swelling, |
||||
DUPILUMAB, |
||||
| 32 | 26557332 |
US |
11 | 1 |
Pruritus, Sleep disorder, Dry skin, Skin haemorrhage, Skin weeping, Feeling hot, Hyperhidrosis, |
||||
DUPILUMAB, |
||||
| 33 | 26557399 |
US |
39 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 34 | 26557421 |
US |
69 | 1 |
Rash macular, Pruritus, Skin burning sensation, Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 35 | 26557436 |
US |
71 | 1 |
Pruritus, Macule, |
||||
DUPILUMAB, |
||||
| 36 | 26557447 |
US |
80 | 1 |
Pruritus, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, METHYLPHENIDATE HYDROCHLORIDE, ALBUTEROL SULFATE, |
||||
| 37 | 26557465 |
US |
2 | |
Pruritus, |
||||
DUPILUMAB, |
||||
| 38 | 26557473 |
US |
2 | |
Dry skin, Pruritus, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, ROSUVASTATIN CALCIUM, ALBUTEROL SULFATE, |
||||
| 39 | 26557541 |
US |
2 | |
Discomfort, Rash, Pruritus, Pain, Product dose omission issue, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 40 | 26557545 |
US |
31 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 41 | 26557549 |
US |
58 | 2 |
Psoriasis, Dermatitis, Dermatitis psoriasiform, Pruritus, |
||||
DUPILUMAB, |
||||
| 42 | 26557552 |
US |
30 | 2 |
Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 43 | 26557560 |
US |
2 | |
Pruritus, |
||||
DUPILUMAB, |
||||
| 44 | 26557588 |
US |
62 | 1 |
Dermatitis atopic, Eczema, Skin exfoliation, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 45 | 26557598 |
US |
64 | 2 |
Dyspnoea, Product dose omission issue, Pruritus, |
||||
DUPILUMAB, |
||||
| 46 | 26557617 |
US |
21 | 2 |
Pharyngitis streptococcal, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 47 | 26557618 |
US |
25 | 2 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 48 | 26557631 |
US |
11 | 1 |
Dry skin, Pruritus, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 49 | 26557831 |
US |
2 | |
Hepatic enzyme increased, Pruritus, |
||||
GUSELKUMAB, |
||||
| 50 | 26557977 |
US |
32 | 2 |
Dermatitis atopic, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 51 | 26558046 |
US |
||
Rash, Dermatitis, Pruritus, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 52 | 26558050 |
US |
41 | 2 |
Skin ulcer, Fatigue, Eczema, Pruritus, Skin fissures, Skin exfoliation, Dry skin, Sleep disorder due to a general medical condition, Skin haemorrhage, Skin weeping, |
||||
DUPILUMAB, BUPROPION, BUSPIRONE HYDROCHLORIDE, ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN, ASPIRIN, CAFFEINE, TURMERIC, CURCUMA AROMATICA ROOT, INDIAN FRANKINCENSE, GINGER, FEVERFEW, IBUPROFEN, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, UBROGEPANT, |
||||
| 53 | 26558061 |
US |
1 | |
Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, WATER, ACONITUM NAP, ARSENICUM ALB, BORAX, CALC PHOS, GELSENIUM, LYCOPODIUM, PHOSPHORICUM AC, PICRICUM AC, PLUMB MET, SOLIDAGO, FLUTICASONE PROPIONATE, |
||||
| 54 | 26558076 |
US |
2 | |
Pruritus, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 55 | 26558077 |
CN |
67 | 1 |
Burning sensation, Conjunctival hyperaemia, Flushing, Swelling face, Rash erythematous, Pruritus, |
||||
IOHEXOL, |
||||
| 56 | 26558078 |
US |
2 | |
Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 57 | 26558079 |
CN |
42 | 1 |
Vitreous floaters, Pruritus, Contrast media reaction, |
||||
IODIXANOL, IODIXANOL, |
||||
| 58 | 26558081 |
US |
64 | 2 |
Dry skin, Eye pruritus, Skin exfoliation, Pruritus, |
||||
DUPILUMAB, GALCANEZUMAB-GNLM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, IBUPROFEN, ESOMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM, RIZATRIPTAN, |
||||
| 59 | 26558136 |
US |
72 | 2 |
Pruritus, Skin exfoliation, |
||||
DUPILUMAB, ALENDRONATE SODIUM, GABAPENTIN, HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM, LOSARTAN, VITAMIN C, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 60 | 26558145 |
US |
29 | 2 |
Dermatitis, Pruritus, Drug ineffective for unapproved indication, Drug ineffective for unapproved indication, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, PIMECROLIMUS, |
||||
| 61 | 26558146 |
US |
72 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PSYLLIUM HUSK, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 62 | 26558394 |
CN |
78 | 2 |
Anaphylactic shock, Eyelid oedema, Conjunctival oedema, Erythema, Pruritus, Chest discomfort, Tachypnoea, Dizziness, Blood pressure decreased, Heart rate increased, Dyspnoea, Rash, |
||||
TOBRAMYCIN, |
||||
| 63 | 26558811 |
US |
56 | 1 |
Headache, Dry skin, Rash, Pruritus, |
||||
TRALOKINUMAB-LDRM, |
||||
| 64 | 26558848 |
US |
18 | |
Eczema herpeticum, Pain of skin, Skin burning sensation, Pruritus, Eczema, Rash, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, DUPILUMAB, UPADACITINIB, |
||||
| 65 | 26559152 |
US |
2 | |
Urine output decreased, Decreased appetite, Pain, Pruritus, Headache, Peripheral swelling, Peripheral swelling, Joint swelling, Infusion site discharge, |
||||
| 66 | 26559224 |
EU |
58 | 2 |
Palmar-plantar erythrodysaesthesia syndrome, Head discomfort, Pruritus, Palpitations, Skin burning sensation, Abdominal pain, Vomiting, |
||||
SEMAGLUTIDE, ENALAPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 67 | 26559230 |
CA |
45 | 2 |
Abdominal discomfort, Arthralgia, Autoimmune disorder, Blood cholesterol increased, Confusional state, Contusion, Decreased appetite, Deep vein thrombosis postoperative, Drug ineffective, Eye injury, Folliculitis, Gait inability, Gastrointestinal disorder, Headache, Helicobacter infection, Hypertension, Hypoaesthesia, Ill-defined disorder, Impaired healing, Incorrect route of product administration, Infection, Irritable bowel syndrome, Liver disorder, Lower respiratory tract infection, Lupus vulgaris, Maternal exposure during pregnancy, Muscle injury, Musculoskeletal stiffness, Nasopharyngitis, Nausea, Pemphigus, Peripheral swelling, Off label use, Pruritus, Rash, Rheumatic fever, Rheumatoid factor positive, Swelling, Swollen joint count increased, Synovitis, Systemic lupus erythematosus, Vomiting, Wheezing, Wound, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, RITUXIMAB, |
||||
| 68 | 26559232 |
US |
2 | |
Dizziness, Feeling abnormal, Pruritus, Pyrexia, Nausea, Rash, |
||||
DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 69 | 26559363 |
RU |
56 | 2 |
Pruritus, Blood glucose fluctuation, |
||||
INSULIN ASPART INJECTION, INSULIN ASPART, LOSARTAN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ATENOLOL, GABAPENTIN, EZETIMIBE, |
||||
| 70 | 26559506 |
US |
||
Rash, Pruritus, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 71 | 26559858 |
56 | 1 | |
Contrast media allergy, Tachypnoea, Blood pressure decreased, Loss of consciousness, Unresponsive to stimuli, Pulse absent, Apnoea, Oxygen saturation immeasurable, Heart rate abnormal, Pruritus, Dyspnoea, Cyanosis, Conjunctival oedema, Chest discomfort, Erythema, Supraventricular extrasystoles, |
||||
IOPROMIDE, IOPROMIDE, |
||||
| 72 | 26559916 |
US |
58 | 2 |
Hypersensitivity, Rash, Erythema, Swelling, Skin disorder, Pruritus, |
||||
INCLISIRAN, INCLISIRAN, |
||||
| 73 | 26559994 |
US |
48 | |
Rash, Pruritus, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 74 | 26560016 |
US |
76 | 1 |
Pruritus, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, |
||||
| 75 | 26560039 |
|||
Contrast media reaction, Pruritus, Erythema, |
||||
GADOTERIDOL, |
||||
| 76 | 26560092 |
2 | ||
Rash, Pruritus, Dizziness, |
||||
IRON SUCROSE, IRON SUCROSE, |
||||
| 77 | 26560112 |
US |
2 | |
Pruritus, Skin haemorrhage, Scratch, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 78 | 26560119 |
US |
2 | |
Cerebrovascular accident, Seizure, Pruritus, |
||||
DUPILUMAB, |
||||
| 79 | 26560122 |
US |
75 | 1 |
Pruritus, Therapeutic response decreased, |
||||
DUPILUMAB, ACARBOSE, LOSARTAN POTASSIUM, LOSARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ROSUVASTATIN, TAMSULOSIN HYDROCHLORIDE, |
||||
| 80 | 26560125 |
US |
59 | 1 |
Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 81 | 26560221 |
US |
74 | 1 |
Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 82 | 26560229 |
US |
23 | 2 |
Rash erythematous, Pruritus, Burning sensation, Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 83 | 26560241 |
US |
17 | 1 |
Hypersensitivity, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 84 | 26560247 |
US |
66 | 1 |
Rash erythematous, Skin burning sensation, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 85 | 26560250 |
US |
67 | 2 |
Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 86 | 26560252 |
US |
54 | 1 |
Rash, Pruritus, Skin burning sensation, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 87 | 26560265 |
US |
66 | 2 |
Dyspnoea, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 88 | 26560269 |
US |
82 | 2 |
Sleep disorder, Skin fissures, Skin exfoliation, Dry skin, Pruritus, |
||||
DUPILUMAB, GARLIC, LOSARTAN POTASSIUM, LOSARTAN, CETIRIZINE HYDROCHLORIDE, POLYETHYLENE GLYCOL 3350, DULOXETINE HYDROCHLORIDE, DULOXETINE, MONTELUKAST SODIUM, GABAPENTIN, CONJUGATED ESTROGENS, ESTROGENS, CONJUGATED, ISOSORBIDE MONONITRATE, PITAVASTATIN CALCIUM, FOLIC ACID, LEVOTHYROXINE SODIUM, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, EPINEPHRINE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, AMMONIUM LACTATE, |
||||
| 89 | 26560272 |
US |
50 | 1 |
Eczema, Skin irritation, Pruritus, Rash, |
||||
DUPILUMAB, DUPILUMAB, UPADACITINIB, |
||||
| 90 | 26560274 |
US |
59 | 2 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 91 | 26560275 |
US |
88 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 92 | 26560287 |
US |
55 | 1 |
Rash macular, Pruritus, Eczema, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 93 | 26560293 |
US |
2 | |
Pruritus, |
||||
DUPILUMAB, |
||||
| 94 | 26560294 |
US |
50 | 1 |
Eczema, Pruritus, Rash, Skin discolouration, Product dose omission in error, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 95 | 26560323 |
US |
35 | 1 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, SECUKINUMAB, |
||||
| 96 | 26560325 |
US |
88 | 1 |
Wheezing, Pruritus, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, AMLODIPINE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, RIVAROXABAN, |
||||
| 97 | 26560341 |
US |
33 | 1 |
Dry skin, Eyelid skin dryness, Pruritus, Erythema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 98 | 26560343 |
US |
56 | 2 |
Dyshidrotic eczema, Pruritus, Skin irritation, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 99 | 26560367 |
US |
1 | |
Rash erythematous, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 100 | 26560373 |
US |
75 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dry skin, Peripheral swelling, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28
